Epilepsy is one of the most common disarrays of the brain in the world. It is a disorder in which a person has frequent seizures due to a chronic, fundamental process [1]. This generally occurs because of unwarranted neuronal discharge in the brain [2]. Different areas of the brain may be involved. The characteristics of seizures differ and are dependent on where the commotion first begins in the brain and how far it extends [3]. Epilepsy has been described as Apasmara in the prehistoric Indian literature around 500-1000 BC [4].

Around 2.4 million people are diagnosed with epilepsy each year worldwide. 70% to 80% of people who have epilepsy can lead normal lives if they are properly treated [3]. In about 70% of cases, there is no understandable cause. This type of epilepsy often arises in childhood [5], with a high prevalence of about 0.8% below the age of 7 y [6].

The hazard of epilepsy is maximum throughout the first year of life, and it diminishes during childhood and adolescence, but in the age range of 50-60 y the threat starts to increase again. According to the Rochester study approximately 50% of cases of epilepsy begin in childhood or adolescence [7], but in other epidemiological studies, 75-90% of cases of epilepsy have started before adulthood [8]. The overall collective occurrence of epilepsy has varied between 1-3% in various studies and epilepsy seems to be more common in men than in women [9].

A significant number of drugs are accessible for the treatment of different types of seizures. The aim is to decrease the incidence and severity of seizures within a scaffold of a suitable level of side effects. A perfect anti-epileptic drug would restrain all seizures without causing any untoward consequence, but unluckily the drugs that are used currently not only fail to suppress seizure activity in some patients, they also produce recurrent adverse effects [10]. The copious side effect profile of the currently available antiepileptic drugs (AEDs) are of utmost distress for both the patients and their physicians.

Numerous efforts have been made previously to get hold of anticonvulsant drugs from plant sources and these attempts will continue until a suitable treatment option is obtainable [11]. Natural products from folk remedies have made significant contributions in the breakthrough innovation of modern drugs and can serve as an alternative option for the discovery of AEDs with novel structures and better tolerance [12].

**Centella asiatica** is a clonal, perennial herbaceous creeper belonging to the family Umbellifere (Apiceae). It is found all over India growing in damp places up to an height of 1800 m. Commonly known as Manukpurnari or Indian pennywort or Jalabhrimi, it has been used as a medicine in the Ayurvedic tradition of India for thousands of years and listed in the historic ‘Sushruta Samhita’, an ancient Indian medical text. **Centella asiatica** has been widely used in ayurveda for the treatment of epilepsy, various skin diseases, leprosy and malaria [13]. From the literature it is evident that **Centella asiatica** has been used in epilepsy and also that the plant is easily accessible in our place the present study was undertaken to study the anticonvulsant activity of aqueous extract of **Centella asiatica** in albino mice.

Male albino mice weighing 18–30 g were obtained from the animal house, Silchar Medical College and Hospital, Silchar, Assam and kept in the departmental polypropylene cages and acclimatised for 10 d. All test animals are allowed free access to food and water ad libitum, both being withdrawn just prior to experimentation. Twelve hours dark-light cycle was maintained.

The chemicals used in the study were Pentylenetetrazole (from Sigma Aldrich), Valproic acid (from Sun pharmaceuticals), Phenytion (from Abbott Pharmaceuticals).
The design of the study is as follows:

The plant was collected from the vicinity of basic science building (SMCH). It was authenticated by Dr. Ashis Nath (Associate professor, Department of Botany, G. C. College, Silchar [No./GCC/SIL/2014/198]) and was cleaned with water and air dried in the shade. It was then powdered using a mixture grinder. 30 g of the powder was soaked in 200 ml of cold water for ~ 18 hr at room temperature. The extract was first filtered through Whatman no. 1 filter paper to clarify and then through a 0.45 μm membrane filter [14]. The filtrate was evaporated to dryness at room temperature in a steady air current and the yield recorded as a percentage of the quantity of initial plant material used. The filtrate was evaporated to dryness at room temperature in a steady air current and the yield recorded as a percentage of the quantity of initial plant material used, and it was 33%. The test solution of Centella asiatica was prepared by dissolving 2 g of an aqueous extract of Centella asiatica in 100 ml of distilled water at room temperature. This solution had a concentration of 20 mg/ml.

The mice were subjected to maximal electroshock (MES) convulsions using electro-convulsiometer (INCO, Ambala, India) by applying a current of 50 mA for 0.2 seconds via ear electrodes. The electrodes were moistened with saline solution before application. The resultant seizure passes through various phases: phase of tonic limb flexion, tonic limb extension, clonus, and post-ictal depression followed by recovery or death [15]. The mouse was considered as protected if the drug prevented the appearance of hind limb tonic extensor component of the seizure.

In the PTZ method, the mice received 80 mg/kg of PTZ subcutaneously [15]. Each mice was pretreated with drugs one hour before giving PTZ. Only those animals that exhibited a convulsive response in the form of clonus, tonic fore and hind limb flexion, tonic limb extension, post-ictal depression followed by recovery or death were used for the experiment. In this method abolition of tonic, hind limb extension phase was considered as protection conferred by the drug. The results of this study are expressed as mean ± standard error of mean (mean±SE). Results are analysed by ANOVA and post hoc test was done by Tukey-Kramer multiple comparisons test. The significance is established when probability value (p-value) is less than 0.05. P values are denoted as *<p<0.05 as significant, **<p<0.01 as highly significant and ***<p<0.001 as very highly significant.

The Institutional Ethics Committee, Silchar Medical College, Silchar approved the protocol of the study (SMCH/IEC/SIL/2013/12-067).

The mean duration of tonic hind limb flexion, tonic hind limb extension, clonus, post-ictal depression and seizure latency (in case of PTZ method) are recorded for different test dose of Centella Asiatica (T1 200 mg/kg and T2 400 mg/kg for MES method and T3 200 mg/kg and T4 400 mg/kg for PTZ method) and findings are compared with the mean duration of above-mentioned parameters recorded for the control group used for both PTZ and MES method.

### Table 1: It shows comparison of mean duration (in seconds) with control group of different parameters in MES method

<table>
<thead>
<tr>
<th>Parameters duration in second</th>
<th>Group C1</th>
<th>Group S1</th>
<th>Group T1</th>
<th>Group T2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tonic hind limb flexion</td>
<td>2.67±0.4216</td>
<td>0***</td>
<td>0.75±0.359*</td>
<td>0.33±0.333***</td>
</tr>
<tr>
<td>Tonic hind limb extension</td>
<td>12.33±0.1464</td>
<td>0***</td>
<td>11.33±2.30ns</td>
<td>1.83±1.47**</td>
</tr>
<tr>
<td>Clonus</td>
<td>22.8±1.249</td>
<td>11.2±0.7491***</td>
<td>11.5±2.46***</td>
<td>13.3±1.542**</td>
</tr>
<tr>
<td>Post ictal depression</td>
<td>173±8.819</td>
<td>0***</td>
<td>257±5.268***</td>
<td>12.5±6.021***</td>
</tr>
</tbody>
</table>

Data are expressed as MEAN±SE. *<p<0.05, **<p<0.01, ***<p<0.001 (compared with control). N=6, ns=not significant. One way ANOVA followed by Tukey-Kramer multiple comparisons test.

### Table 2: Shows Comparison of mean duration (in seconds) with control group of different parameters in PTZ method

<table>
<thead>
<tr>
<th>Parameters duration in second</th>
<th>Group C2</th>
<th>Group S2</th>
<th>Group T3</th>
<th>Group T4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seizure latency</td>
<td>325.5±14.11</td>
<td>0***</td>
<td>43.5±411***</td>
<td>0***</td>
</tr>
<tr>
<td>Tonic hind limb flexion</td>
<td>1.75±0.21</td>
<td>0***</td>
<td>1.75±0.201**</td>
<td>0***</td>
</tr>
<tr>
<td>Tonic hind limb extension</td>
<td>9.83±0.6</td>
<td>0***</td>
<td>9.83±0.6**</td>
<td>0***</td>
</tr>
<tr>
<td>Clonus</td>
<td>4.83±0.61</td>
<td>0***</td>
<td>3.67±0.56**</td>
<td>0***</td>
</tr>
<tr>
<td>Post ictal depression</td>
<td>33.6±5.38</td>
<td>0***</td>
<td>279.83±1.511***</td>
<td>0***</td>
</tr>
</tbody>
</table>

Data are expressed as MEAN±SE. *<p<0.05, **<p<0.01, ***<p<0.001 (compared with control). N=6, ns=not significant. One way ANOVA followed by Tukey-Kramer Multiple Comparisons test.
From table 1 it was evident that there was a decrease in the mean duration of tonic hind limb extension for both the test dose (T1 200 mg/kg and T2 400 mg/kg) and it was highly significant compared with control for T2, it was statistically not significant for T1 with compared with control.

From table 2 it was observed that the decrease in mean duration of tonic hind limb extension was only statistically significant compared with control T4 (400 mg/kg of Centella asiatica).

In this study, for the screening of aqueous extract of Centella asiatica for anticonvulsant activity, two standard methods namely MES and PTZ methods had been used [16]. The parameters observed were the duration of tonic hind limb flexion, tonic hind limb extension, clonus, post-ictal depression and incidence of recovery and death. In both MES and PTZ methods, the mouse was considered protected if the drug abolished the tonic hind limb extension [14].

In MES method, comparison of mean duration of tonic hind limb extension of control group (12.33±0.6146) with test groups indicate that there is a decrease in mean duration of tonic hind limb extension in both groups T1 (11.33±2.305) and T2 (1.83±1.47) and it is statistically significant (p<0.001) only in group T2. In group S1, there is the complete abolition of tonic hind limb extension which is statistically significant (p<0.001). A comparison of test groups T1 (11.33±2.305) and T2 (1.83±1.47) with group S1 (0±0.00), indicate that there is a significant difference between S1 and T1 (p<0.001), while no significant difference between S1 and T2. Since abolition of tonic hind limb extension is considered suggestive of protection against MES convulsions [15] and standard antiepileptic drugs such as phenytoin, valproate and lamotrigine, which are clinically proven to be competent in the treatment of generalized tonic-clonic and partial seizures, all abolish the hind limb tonic extension in the MES model [17, 18], the aqueous extract of Centella asiatica has anticonvulsant effect against MES convulsions at a dose of 400 mg/kg. This effect is comparable to that of phenytoin in this study.

In PTZ method, comparison of mean duration of tonic hind limb extension of control group (9.83±0.307) with test groups and standard indicates that there is no significant difference between group C2 (9.83±0.307) and group T3 (9.83±0.601), while in groups S2 and T4, there is abolition of tonic extensor phase which is statistically significant (p<0.001) compared to control group. Comparison of mean duration of tonic hind limb extension of standard group S2 (0±0.00) with test groups T3 (9.83±0.601) and T4 (0±0.00) indicates that there is a significant difference between group S2 and group T3 (p<0.001), while no significant difference between group S2 and group T4.

The abolition of tonic hind limb extension has occurred in all mice in group T4 while in group T3 there is no abolition of tonic hind limb extension. Since the abolition of tonic hind limb extension is considered suggestive of protection against MES and PTZ convulsions [14, 15], the aqueous extract of Centella asiatica has anticonvulsant effect against PTZ convulsions at a dose of 400 mg/kg. This effect is comparable to that of sodium valproate in this study.

From our study, we can conclude that aqueous extract of Centella asiatica has shown efficacy in both MES and PTZ convulsions in mice at a dose of 400 mg/kg. Further studies are required to estimate the exact mechanisms, active principles and safety of the plant as a medicinal remedy for epilepsy.

We would like to thank Dr. Dolly Roy, Associate Professor of the department of Pharmacology, Sikchar Medical College and Hospital for her valuable suggestions during our study. We also thank Dr. Ashis Nath, Associate professor, Department of Botany, G. C. College, Sikhar for his help in taxonomical identification. Also, we would like to thank ADRs monitoring centre, Pharmacovigilance Programme of India (PvPI) under Indian Pharmacopoeia Commission (IPC) for their support during the research.

CONFLICT OF INTERESTS

Declared none

REFERENCES


How to cite this article